Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
Caligan Partners to Vote “FOR” Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney , a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL
View HTML
Toggle Summary Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
Company Urges ALL Stockholders to Vote “FOR” the Proposals at the Special Meeting Parties to Terminate the Purchase Agreements if Stockholder Approval is Not Received on April 1 SOUTH SAN FRANCISCO, Calif. , March 28, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that
View HTML
Toggle Summary Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors SOUTH SAN FRANCISCO, Calif. , March 25, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it convened and then adjourned, without
View HTML
Toggle Summary Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
Cash Investment Expected to Significantly Advance Fluidigm’s Mission through New Growth Initiatives and Cost Structure Optimization SOUTH SAN FRANCISCO, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today urged Fluidigm stockholders to vote “FOR” ALL proposals
View HTML
Toggle Summary Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY SOUTH SAN FRANCISCO, Calif. , March 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), today announced that leading independent proxy advisory firms Institutional Shareholder Services
View HTML
Toggle Summary Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results
SOUTH SAN FRANCISCO, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the fourth quarter and full year ended December
View HTML
Toggle Summary Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell Therapies
Collaboration Enables Further Expansion of Mass Cytometry in the Middle East SOUTH SAN FRANCISCO, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today
View HTML
Toggle Summary Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for a special meeting of stockholders (the “Special Meeting”) at which Fluidigm stockholders will
View HTML
Toggle Summary Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.
Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions Dr. Michael Egholm , Former CTO of Danaher Life Sciences, to Assume Role of CEO and Join Board of Directors Following Close; Alex Kim , Former
View HTML
Toggle Summary Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021
Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base product and service revenue growth of approximately 13% for fourth quarter and 12% for full year as new Biomark OEM and CyTOF XT instruments  contributed to revenue SOUTH
View HTML